

Integrated Filing-Governance

General information about company	
Scrip Code	000000
NSE Symbol	BETA
MSEI Symbol	NOTLISTED
ISIN	INE351Y01019
Name of the entity	BETA DRUGS LIMITED
Date of start of financial year	01-Apr-2025
Date of end of financial year	31-Mar-2026
Reporting Quarter	Yearly
Date of Quarter Ending	31-Mar-2026
Type of company	Equity
Whether Annexure I (Part A) of the SEBI Circular dated December 31, 2024 related to Compliance Report on Corporate Governance is applicable to the entity?	Yes
Whether Annexure I (Part B) of the SEBI Circular dated December 31, 2024 related to Investor Grievance Redressal Report is Applicable to the entity?	Yes
Whether Annexure I (Part C) of the SEBI Circular dated December 31, 2024 related to Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies is Applicable to the entity?	No
Reason For Part C Of Annexure I Disclosure Of Acquisition Of Shares Or Voting Rights In Unlisted Companies Is Not Applicable To The Entity	.
Whether Annexure I (Part D) of the SEBI Circular dated December 31, 2024 related to Disclosure of Imposition of Fine or Penalty is Applicable to the entity?	No
Reason For Part D Of Annexure I Disclosure Of Imposition Of Fine Or Penalty Is Not Applicable To The Entity	Not applicable.
Whether Annexure I (Part E) of the SEBI Circular dated December 31, 2024 related to Disclosure of Updates to Ongoing Tax Litigations or Disputes is Applicable to the entity?	No
Reason For Part E Of Annexure I Disclosure Of Updates To Ongoing Tax Litigations Or Disputes Is Not Applicable To The Entity	Not applicable.
Whether Annexure I (Part F) of the SEBI Circular dated December 31, 2024 related to Disclosure Of Loans / Guarantees / Comfort Letters / Securities Etc. is Applicable to the entity?	Yes
Risk management committee	No
Market Capitalisation as per immediate previous Financial Year	Top 2000 listed entities
Is SCORE ID Available ?	Yes
SCORE Registration ID	COMZ00121
Reason For No SCORE ID	
Type of Submission	Original
Remarks (website dissemination)	

Annexure I
Annexure I to be submitted by listed entity on quarterly basis
I. Composition of Board of Directors

Disclosure of notes on composition of board of directors explanatory										
Whether the listed entity has a Regular Chairperson										
Whether Chairperson is related to MD or CEO										
Disqualification of Directors under										
Sr	Title (Mr / Ms)	Name of the Director	PAN	DIN	Category 1 of directors	Category 2 of directors	Category 3 of directors	Date of Birth	Whether the director is disqualified?	Start Date of disqualification
1	Mr.	RAHUL BATRA		02229234	Executive Director	Chairperson	MD	08-Oct-1984	No	
2	Mr.	VARUN BATRA		02148383	Executive Director	Not Applicable	MD	15-Jun-1985	No	
3	Mr.	BALWANT SINGH		01089968	Executive Director	Not Applicable		04-Apr-1970	No	
4	Mr.	ASHUTOSH SHUKLA		09461568	Executive Director	Not Applicable		07-Sep-1977	No	
5	Mr.	MANMOHAN KHANNA		07888319	Non-Executive - Independent Director	Not Applicable		05-Oct-1953	No	
6	Mr.	ROHIT PARTI		07889944	Non-Executive - Independent Director	Not Applicable		24-Nov-1975	No	
7	Mrs.	MONICA JAIN		05253864	Non-Executive - Independent Director	Not Applicable		06-Apr-1971	No	
8	Mr.	LALIT KUMAR WATTS		10906518	Non-Executive - Independent Director	Not Applicable		07-Oct-1960	No	
9	Mr.	SANJAY SEHGAL		01235531	Non-Executive - Independent Director	Not Applicable		24-Aug-1961	No	
10	Mr.	AJAY MAHIPAL		06949940	Non-Executive - Non Independent Director	Not Applicable		06-Sep-1981	No	

Annexure 1	
II. Composition of Committees	
Disclosure of notes on composition of committees explanatory	

Audit Committee Details

Whether the Audit Committee has a Regular Chairperson	Yes
---	-----

Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Ren
1	02229234	RAHUL BATRA	Executive Director	Member	27-Jan-2021		
2	07889944	ROHIT PARTI	Non-Executive - Independent Director	Member	26-Jul-2017		
3	07888319	MANMOHAN KHANNA	Non-Executive - Independent Director	Chairperson	26-Jul-2017		

Nomination and remuneration committee

Whether the Nomination and remuneration committee has a Regular Chairperson	Yes
---	-----

Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Ren
1	02229234	RAHUL BATRA	Executive Director	Member	27-Jan-2021		
2	07889944	ROHIT PARTI	Non-Executive - Independent Director	Member	26-Jul-2017		
3	07888319	MANMOHAN KHANNA	Non-Executive - Independent Director	Chairperson	26-Jul-2017		
4	01235531	SANJAY SEHGAL	Non-Executive - Independent Director	Member	27-Nov-2024		

Stakeholders Relationship Committee

Whether the Stakeholders Relationship Committee has a Regular Chairperson	Yes
---	-----

Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Ren
1	02229234	RAHUL BATRA	Executive Director	Member	27-Jan-2021		
2	07889944	ROHIT PARTI	Non-Executive - Independent Director	Member	26-Jul-2017		
3	07888319	MANMOHAN KHANNA	Non-Executive - Independent Director	Chairperson	26-Jul-2017		

Risk Management Committee

Whether the Risk Management Committee has a Regular Chairperson

Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Rem
1					27-Jan-2021		
2					27-Jan-2021		
3					20-Apr-2018		

Annexure 1

III. Meeting of Board of Directors

Disclosure of notes on meeting of board of directors explanatory

Sr	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Notes for not providing Date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors as on date of the meeting	Number of Directors present* (All directors including Independent Director)	No. of Independent Directors attend the meeting*
1	09-Jan-2026			Yes	10	8	3
2	14-Feb-2026	35		Yes	10	9	5
3	17-Mar-2026	30		Yes	10	10	5

Annexure 1

IV. Meeting of Committees

Disclosure of notes on meeting of committees explanatory

Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending meeting (other than Board of Directors)
1	Audit Committee	09-Jan-2026				Yes	3	3	2	0
2	Nomination and remuneration committee	09-Jan-2026				Yes	4	4	3	0
3	Stakeholders Relationship Committee	09-Jan-2026				Yes	3	3	2	0
4	Audit Committee	14-Feb-2026	35			Yes	3	3	2	0

Annexure 1

VI. Affirmations

Sr	Subject	Compliance status (Yes/No)
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee	Yes
3	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee	Yes
4	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee	Yes
5	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 1000 listed entities)	NA
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	Yes

9	Any comments/observations/advice of Board of Directors may be mentioned here:
---	---

Annexure 1		
Sr	Subject	Compliance status
1	Name of signatory	RAJNI BRAR
2	Designation	Company Secretary and Compliance Officer

Details of Cyber security incidence	
Whether as per Regulation 27(2)(ba) of SEBI (LODR) Regulations, 2015 there has been cyber security incidents or breaches or loss of data or documents during the quarter	No
Other details of cyber security incidence or breaches or loss of data event	
Number of cyber security incidence or breaches or loss of data event occurred during the quarter	

Sr	Date of the event	Brief details of the event
----	-------------------	----------------------------

Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)				
I. Disclosure on website in terms of LODR Regulation				
Sr	Item	Compliance status (Yes/No/NA)	If status is No details of non-compliance may be given here.	Web address
1.1	Details of business	Yes		www.betadrugslimited.com
1.2	Memorandum of Association and Articles of Association	Yes		https://www.betadrugslimited.com/financereports/
1.3	Brief profile of board of directors including directorship and full time positions in body corporates	Yes		https://www.betadrugslimited.com/financereports/
2	Terms and conditions of appointment of independent directors	Yes		https://www.betadrugslimited.com/financereports/
3	Composition of various committees of board of directors	Yes		https://www.betadrugslimited.com/financereports/
4	Code of conduct of board of directors and senior management personnel	Yes		https://www.betadrugslimited.com/financereports/
5	Details of establishment of vigil mechanism or whistle blower policy	Yes		https://www.betadrugslimited.com/financereports/
6	Criteria of making payments to non-executive directors	Yes		https://www.betadrugslimited.com/financereports/
7	Policy on dealing with related party transactions	Yes		https://www.betadrugslimited.com/financereports/
8	Policy for determining material subsidiaries	Yes		https://www.betadrugslimited.com/financereports/
9	Details of familiarization programmes imparted to independent directors	Yes		https://www.betadrugslimited.com/financereports/
10	Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances	Yes		https://www.betadrugslimited.com/financereports/
11	Email address for grievance redressal and other relevant details	Yes		https://www.betadrugslimited.com/investcontacts/
12	Financial results	Yes		https://www.betadrugslimited.com/financereports/
13	Shareholding pattern	Yes		https://www.betadrugslimited.com/financereports/
14	Details of agreements entered into with the media companies and/or their associates	NA		
15.1	Schedule of analyst or institutional investor meet and presentation prepared by listed entity for analyst or institutional investor meet	Yes		https://www.betadrugslimited.com/financereports/
15.2	Audio or video recordings and transcripts of post earnings/quarterly calls	Yes		https://www.betadrugslimited.com/financereports/
16	New name and the old name of the listed entity	Yes		https://www.betadrugslimited.com/financereports/
17	Advertisements as per regulation 47 (1)	Yes		https://www.betadrugslimited.com/financereports/
18	Credit rating or revision in credit rating obtained	NA		
19	Separate audited financial statements of each subsidiary of the listed entity	Yes		https://www.betadrugslimited.com/financereports/
20	Secretarial compliance report	No	Company has migrated from NSE Emerge (SME) to Main Board Platform w.e.f. 24-11-2025. Hence the compliance is applicable on company for FY 2025-26. It will be uploaded on website as and when due and filled with the Stock Exchange.	

21	Materiality policy as per regulation 30 (4)	Yes		https://www.betadrugslimited.com/financereports/
22	Disclosure of contact details of KMP who are authorized for the purpose of determining materiality as required under regulation 30(5)	Yes		https://www.betadrugslimited.com/investcontacts/
23	Disclosures under regulation 30(8)	Yes		https://www.betadrugslimited.com/financereports/
24	Statements of deviation(s) or variations(s) as specified in regulation 32	Yes		https://www.betadrugslimited.com/financereports/
25	Dividend distribution policy as specified in regulation 43A (1)	NA		
26.1	Annual return as provided under section 92 of the Companies Act 2013	Yes		https://www.betadrugslimited.com/financereports/
26.2	Employee benefit scheme documents framed in terms of SEBI (SBEB) regulations 2021			
27	Confirmation that the above disclosures are in a separate section as specified in regulation 46(2)	Yes		https://www.betadrugslimited.com/financereports/
28	Compliance with regulation 46(3) with respect to accuracy of disclosures on the website and timely updation	Yes		https://www.betadrugslimited.com/financereports/
29	Disclosure of notes on website in terms of Listing Regulations explanatory			

Annexure II				
II. Annual Affirmations				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is No details of non-compliance may be given here
1	Independent director(s) have been appointed in terms of specified criteria of independence and/or eligibility	16(1)(b)	Yes	
2	Board Composition	17(1), 17(1A) & 17(1C), 17(1D) & 17(1E)	Yes	
3	Meeting Of Board Of Directors	17(2)	Yes	
4	Quorum of board meeting	17(2A)	Yes	
5	Review of Compliance Reports	17(3)	Yes	
6	Plans for orderly succession for appointments	17(4)	Yes	
7	Code of Conduct	17(5)	Yes	
8	Fees/compensation	17(6)	NA	
9	Minimum Information	17(7)	Yes	
10	Compliance Certificate	17(8)	Yes	
11	Risk Assessment & Management	17(9)	Yes	
12	Performance Evaluation of Independent Directors	17(10)	Yes	
13	Recommendation of Board	17(11)	Yes	
14	Maximum number of Directorships	17A	Yes	
15	Composition of Audit Committee	18(1)	Yes	
16	Meeting of Audit Committee	18(2)	Yes	
17	Role of Audit Committee and information to be reviewed by the audit committee	18(3)	Yes	
18	Composition of nomination & remuneration committee	19(1) & (2)	Yes	
19	Quorum of Nomination and Remuneration Committee meeting	19(2A)	Yes	
20	Meeting of Nomination and Remuneration Committee	19(3A)	Yes	
21	Role of Nomination and Remuneration Committee	19(4)	Yes	
22	Composition of Stakeholder Relationship Committee	20(1), 20(2) & 20(2A)	Yes	
23	Meeting of Stakeholders Relationship Committee	20(3A)	Yes	
24	Role of Stakeholders Relationship Committee	20(4)	Yes	
25	Composition and role of risk management committee	21(1),(2),(3),(4)	NA	
26	Meeting of Risk Management Committee	21(3A)	NA	
27	Quorum of Risk Management Committee meeting	21(3B)	NA	
28	Gap between the meetings of the Risk Management Committee	21(3C)	NA	
29	Vigil Mechanism	22	Yes	
30	Policy for related party Transaction	23(1), (1A), (5), (6), & (8)	Yes	
31	Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	Yes	
32	Approval for material related party transactions	23(4)	Yes	
33	Disclosure of related party transactions on consolidated basis	23(9)	Yes	
34	Composition of Board of Directors of unlisted material Subsidiary	24(1)	Yes	
35	Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2),(3),(4),(5) & (6)	Yes	
36	Alternate Director to Independent Director	25(1)	Yes	
37	Maximum Tenure	25(2)	Yes	
38	Appointment, Re-appointment or removal of an Independent Director through special resolution or the alternate mechanism	25(2A)	Yes	
39	Meeting of independent directors	25(3) & (4)	Yes	

40	Familiarization of independent directors	25(7)	Yes	
41	Declaration from Independent Director	25(8) & (9)	Yes	
42	Directors and Officers insurance	25(10)	NA	
43	Confirmation with respect to appointment of Independent Directors who resigned from the listed entity	25(11)	NA	
44	Memberships in Committees	26(1)	Yes	
45	Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes	
46	Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes	
47	Approval of the Board and shareholders for compensation or profit sharing in connection with dealings in the securities of the listed entity	26(6)	NA	
48	Vacancies in respect Key Managerial Personnel	26A(1) & 26A(2), 26A(3)	NA	
Any other information to be provided - Add Notes				

Annexure II		
III. Affirmations		
Sr	Particulars	Compliance status (Yes/No/NA)
1	The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied	Yes
	Any other information to be provided	

Annexure II		
1	Name of signatory	RAJNI BRAR
2	Designation	Company Secretary and Compliance Officer

Additional Half yearly Disclosure			
Any Other Information for Disclosure of Loans / Guarantees / Comfort Letters / Securities Etc.			
I. Disclosure of Loans/ guarantees/comfort letters /securities etc.refer note below			
(A)Any loan or any other form of debt advanced by the listed entity directly or indirectly to			
Entity	Aggregate amount advanced during six months	Balance outstanding at the end of six months	
Promoter or any other entity controlled by them	0	0	
Promoter Group or any other entity controlled by them	0	0	
Directors (including relatives) or any other entity controlled by them	0	0	
KMPs or any other entity controlled by them	0	0	
(B) Any guarantee / comfort letter (by whatever name called) provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed By			
Entity	Type (guarantee, comfort letter etc.)	Aggregate amount of issuance during six months	Balance outstanding at the end of six months(taking into account any invocation)
Promoter or any other entity controlled by them	0	0	0
Promoter Group or any other entity controlled by them	0	0	0
Directors (including relatives) or any other entity controlled by them	0	0	0
KMPs or any other entity controlled by them	0	0	0
(C) Any security provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed by			
Entity	Type of security (cash, shares etc.)	Aggregate value of security provided during six months	Balance outstanding at the end of six months
Promoter or any other entity controlled by them	0	0	0
Promoter Group or any other entity controlled by them	0	0	0
Directors (including relatives) or any other entity controlled by them	0	0	0
KMPs or any other entity controlled by them	0	0	0
(D) Additional Information			
II. Affirmations			
Affirmations	Compliance Status	Company Remarks	
All loans (or other form of debt), guarantees, comfort letters (by whatever name called) or securities in connection with any loan(s) (or other form of debt) given directly or indirectly by the listed entity to promoter(s), promoter group, director(s) (including their relatives), key managerial personnel (including their relatives) or any entity controlled by them are in the economic interest of the company.	Yes		
Name	NIPUN ARORA		
Designation	Chief Financial Officer		
Place	PANCHKULA		
Date	10-Apr-2026		

Signatory Details	
Name of signatory	RAJNI BRAR
Designation of person	Company Secretary and Compliance Officer
Place	PANCHKULA
Date	10-Apr-2026

Investor Grievance Details	
No. of investor complaints pending at the beginning of Quarter	0
No. of investor complaints received during the Quarter	0
No. of investor complaints disposed off during the Quarter	0
No. of investor complaints those remaining unresolved at the end of the Quarter	0

Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies- The details of acquisition of shares or voting rights in unlisted companies during the quarter in terms of sub-para 1 of para A of Part A of Schedule III are given below					
Any Other Information for Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies					
Sr. No.	Name of the unlisted company in which shares or voting rights have been acquired	Date of acquisition	Aggregate holding (% shares or voting rights) as at the end of the previous quarter	% shares or voting rights acquired during the quarter	Aggregate holding (% shares or voting rights) as at the end of the quarter

Disclosure of Imposition of Fine or Penalty

The details of imposition of fine or penalty during the quarter in terms of sub-para 20 of para A of Part A of Schedule III are given below:

Any Other Information for Disclosure of Imposition of Fine or Penalty					
Sr. No.	Name of the authority	Nature and details of the action(s) taken or order(s) passed	Date of receipt of direction or order, including any ad interim or interim orders, or any other communication from the authority	Details of the violation(s)/ contravention(s) committed or alleged to be committed	Impact on financial, operation or of activities of the listed entity, quantifiable in monetary terms to the extent possible

Disclosure of Updates to Ongoing Tax Litigations or Disputes

The updates on tax litigations or disputes in terms of sub-para 8 of para B of Part A of Schedule III read with corresponding provisions of Annexure 18 of the Master Circular are given below:

Any Other Information for Disclosure of Updates to Ongoing Tax Litigations or Disputes				
Sr. No.	Name of the opposing party	Date of initiation of the litigation / dispute	Status of the litigation / dispute as per last disclosure	Current status of the litigation dispute

